Could six months of immunotherapy be enough for melanoma? major trial launches
NCT ID NCT06488482
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large phase 3 trial is testing whether giving immunotherapy for 6 months after surgery for high-risk melanoma is as effective as the standard 12-month course. The study aims to enroll 1,792 adults who have had their melanoma surgically removed. If shorter treatment works, it could mean fewer side effects and less time in the hospital for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab or pembrolizumab (immunotherapy drugs, also known as Opdivo and Keytruda)
- What this could lead to
- If successful, this could show that a shorter course of immunotherapy after melanoma surgery is just as effective as the standard one-year treatment, reducing side effects and hospital visits.
- What could go wrong
- This is an early-stage comparison study, and it's possible that 6 months of treatment may not prevent cancer recurrence as well as 12 months. Also, previous studies have not shown that this type of immunotherapy improves overall survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Akershus University Hospital
RECRUITINGOslo, Norway
Contact
-
Eskilstuna Hospital
RECRUITINGEskilstuna, Sweden
Contact
-
Falu Hospital
RECRUITINGFalun, Sweden
Contact
-
Gävle Hospital
RECRUITINGGävle, Sweden
Contact
-
Haukeland University Hospital
RECRUITINGBergen, Norway
Contact
-
Helsinki University Hospital
RECRUITINGHelsinki, Finland
Contact
-
Kalmar Hospital
RECRUITINGKalmar, Sweden
Contact
-
Karlstad Hospital
RECRUITINGKarlstad, Sweden
Contact
-
Karolinska University Hospital
RECRUITINGStockholm, Sweden
Contact
-
Kuopio University Hospital
RECRUITINGKuopio, Finland
Contact
-
Linköping University Hospital
RECRUITINGLinköping, Sweden
Contact
-
North Norway University Hospital
RECRUITINGTromsø, Norway
Contact
-
Oslo University Hospital
RECRUITINGOslo, Norway
Contact
-
Ryhov Hospital
RECRUITINGJönköping, Sweden
Contact
-
Sahlgrenska University Hospital
RECRUITINGGothenburg, Sweden
Contact
-
Skåne University Hospital
RECRUITINGLund, Sweden
Contact
-
Sorlandet Hospital
RECRUITINGKristiansand, Norway
Contact
-
Stavanger University Hospital
RECRUITINGStavanger, Norway
Contact
-
Sundsvall Hospital
RECRUITINGSundsvall, Sweden
Contact
-
Tampere University Hospital
RECRUITINGTampere, Finland
Contact
-
Trondheim University Hospital
RECRUITINGTrondheim, Norway
Contact
-
Turku University Hospital
RECRUITINGTurku, Finland
Contact
-
Västmanland Hospital
RECRUITINGVästerås, Sweden
Contact
-
Växjö Hospital
RECRUITINGVaxjo, Sweden
Contact
-
Ålesund Hospital
RECRUITINGÅlesund, Norway
Contact
-
Örebro University Hospital
RECRUITINGÖrebro, Sweden
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- App aims to help melanoma survivors catch skin cancer early
- Could a jolt of electricity make immunotherapy work better for melanoma?
- Tiny study tests radiation boost to immunotherapy in Hard-to-Treat cancers
- Experimental virus vaccine takes on multiple cancers in early trial
- New drug combo shows promise in early cancer trial
- Melanoma vaccine study pulled before starting